

Ramya Nityanandam

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3970359/ramya-nityanandam-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11

papers

3,007

citations

10

h-index

12

g-index

12

ext. papers

3,715

ext. citations

32.7

avg, IF

4.22

L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 11 | DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020 , 369, 806-811 | 33.3 | 748 |
| 10 | SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020 , 369, 812-817 | 33.3 | 592 |
| 9 | Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020 , 586, 583-588 | 50.4 | 550 |
| 8 | Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016 , 353, 1129-32 | 33.3 | 386 |
| 7 | Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016 , 354, 237-240 | 33.3 | 284 |
| 6 | Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020 , 26, 1694-1700 | 50.5 | 176 |
| 5 | Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. <i>Cell</i> , 2017 , 169, 610-620.e14 | 56.2 | 139 |
| 4 | Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , 2017 , 9, | 17.5 | 80 |
| 3 | BCA2/Rabring7 targets HIV-1 Gag for lysosomal degradation in a tetherin-independent manner. <i>PLoS Pathogens</i> , 2014 , 10, e1004151 | 7.6 | 25 |
| 2 | Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors. <i>Journal of Virology</i> , 2018 , 92, | 6.6 | 16 |
| 1 | Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021 , 27, 1718-1724 | 50.5 | 5 |